

NHS trust boards meet in public, and the public seldom attends. At Greater Manchester Mental Health NHS Foundation Trust, the papers that matter over the coming months will be read by a small audience of regulators, commissioners, relatives of people who have used its services and a handful of journalists. They will find a board in motion. The chair, Tony Warne, leaves at the end of December 2026 after less than three years in post. Four executive director roles are filled on an interim basis. Chief executive Chris Oliver has brought in six new executive and non-executive directors, including a deputy chief executive and a chief operating officer.
The trust is already rated inadequate overall. It has received Section 29A warning notices over its adult community and crisis care, the formal mechanism the Care Quality Commission uses when it judges that significant improvement is needed. Culture and patient safety have been under scrutiny for years. What distinguishes the latest regulatory review is its subject. The well-led assessment, which is still under way, identifies strategic misalignment between the chair and the incoming chief executive, gaps in executive capability and a sense that senior leaders had drifted from the clinical reality of the wards and community teams. It also finds that remedial actions required after the July 2023 inspection had not been fully implemented.
That last point deserves more attention than the personnel changes. More than three years is a long time for a board to carry unfinished obligations from an inspection report. Action plans are the ordinary currency of regulatory recovery, and a trust that cannot close them is telling the regulator something about its internal assurance. Boards are meant to ask whether what they have been told is happening is in fact happening. If the answer is repeatedly unclear, the failure lies in the machinery of oversight itself, and no single poor decision explains it.
The relationship between chair and chief executive is the hinge of that machinery. The chair sets the tone of challenge and holds the executive to account, while the chief executive runs the organisation day to day. When the two disagree about direction, the board lacks a stable centre, and non-executives are left to arbitrate between them. Whether Warne's departure follows from the inspectors' finding is a matter the published record does not settle, and it would be unwise to assume a simple sequence. The more useful observation is that a trust under enforcement cannot afford a contested top table, because the people on the wards take their cues from it.
There is a national context that gives the episode weight beyond Manchester. The government is reshaping the centre of the health service, folding NHS England into the Department of Health and Social Care and promising firmer consequences for persistently underperforming organisations. Published league tables and oversight segmentation now rank trusts publicly. That agenda assumes a supply of capable leaders willing to take on difficult organisations, and a regulatory system able to tell when improvement is real. A trust with four interim executives suggests the supply is thinner than the rhetoric implies. Experienced directors weigh the reputational risk of joining an organisation under warning notices, and short-term appointments are the predictable result.
Mental health sits awkwardly in this politics. Waiting list targets for elective care dominate ministerial attention and national performance reporting, while crisis and community mental health services, where harm can be severe and hard to see, attract scrutiny mainly after something has gone wrong. A governance failure in such a trust tends to surface late and to be framed as a local matter. It is better understood as a test of whether the new accountability framework can reach services that fall outside the headline metrics.
The practical implications are specific. Chairs and chief executives elsewhere should treat the closure of past inspection actions as a standing board agenda item with named owners and independent verification, since the GMMH findings suggest that assurance can fail quietly. Policymakers should accept that a warning notice compels a trust to improve without giving it the people to do so, and that regional and national support for recruiting credible interim and substantive leaders belongs inside the enforcement model. Suppliers of patient safety, incident reporting and clinical systems should plan for slow, careful buying in trusts of this kind, because the executives who commission a contract may have left before it is signed. Patients and families have the least leverage and the most at stake, which is why the transparency of the process matters.
That transparency has an accessible form. The trust publishes its board meeting schedule, and the search for Warne's successor will be visible there. The appointment will show what kind of chair the trust believes it needs and whether the regulator regards the arrangement as credible. The harder test comes later. A reconstituted board earns confidence only when the next inspection finds the old actions closed and the new executives still in post, and until then the changes in Manchester remain a promise of governance and not yet its evidence.